1. Pathophysiologic Targets of Allergic Asthma

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Defining Allergic Asthma

5. FDA-Approved Agents for Severe Allergic Asthma Not a One-Size-Fits-All Therapy

6. Clarifying the Allergic Asthma Phenotype

7. Pathophysiology of Allergic Asthma

8. Asthma: A Heterogenous Disease With Multiple Phenotypes

9. Drivers of Allergic Asthma

10. IL-5

11. IL-4

12. IL-13

13. Inflammatory Mechanisms of Allergic Asthma

14. Mast Cells

15. Concluding Remarks

16. Therapeutic Targets for Severe Allergic Asthma

17. FDA-Approved Agents for Severe Allergic Asthma and Their Targets

18. Clinical Implications of TH2 Biomarkers

19. Eosinophil Levels Vary Over Time in Patients With Severe Asthma

20. Baseline Clinical Factors and Blood Eosinophil Count Can Help Identify Patients Who Are Potentially Responsive to Benralizumab

21. Liberty Asthma QUEST: Phase 3 Study of Efficacy of Dupilumab on Inflammatory Biomarkers of Asthma in Patients With/Without Allergic Rhinitis

22. Liberty Asthma QUEST: Phase 3 Study of Efficacy of Dupilumab on Inflammatory Biomarkers of Asthma in Patients With/Without Chronic Rhinosinusitis/Nasal Polyps

23. Baseline Blood Eosinophil Levels and/or Clinical Markers of Asthma Severity Predict Response to Omalizumab in Patients With Allergic Asthma

24. Concluding Remarks

25. Clinical Impact of Targeting Allergic Asthma

26. Severe Allergic Asthma: Links Between Exacerbations and Outcomes

27. Preseasonal Treatment With Omalizumab or ICS Boost in Children to Prevent Asthma Exacerbation in the Fall Season

28. Omalizumab in Pediatric Patients With Allergic Asthma and Allergic Rhinitis

29. PROSPERO: Outcomes After Initiation of Omalizumab in a Real-World Setting

30. PROSPERO: What Did We Learn?

31. Comorbidities in Patients With TH2-Asthma Substantially Increase Risk of Asthma Exacerbations

32. Dupilumab for Adults With Concurrent Asthma, Atopic Dermatitis, and Sinonasal Conditions

33. Liberty Asthma QUEST: Dupilumab for Asthma With Allergic Asthma

34. Mepolizumab for Asthma With Allergic Rhinitis, Chronic Rhinosinusitis, and/or Nasal Polyps

35. Concluding Remarks

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)